The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.

Jason Liebowitz, MD, FACR, an assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons. He completed undergraduate studies at Johns Hopkins University, Baltimore, where he was inducted into Phi Beta Kappa. He attended medical school at Johns Hopkins School of Medicine and completed his Internal Medicine residency at Johns Hopkins Bayview Medical Center, where he served as chief resident. He completed his rheumatology fellowship at Johns Hopkins Hospital and was honored with the 2019 Distinguished Fellow Award from the American College of Rheumatology. His research and writings have been published in The New England Journal of Medicine, JAMA, JAMA Internal Medicine, Arthritis Care and Research and The Journal of Graduate Medical Education, among other journals. He participated in fellowships with the American Federation for Aging Research (Medical Student Training in Aging Research), the American Austrian Foundation (Max Kade Clinical Clerkship in Vienna, Austria), and the fellowships at Auschwitz for the Study of Professional Ethics (through Yale School of Medicine). He is a co-editor of the textbook Clinical Innovation in Rheumatology: Past, Present, and Future, a co-editor of the book Masterclass in Medicine: Lessons from the Experts, and a co-editor of the textbook series Interdisciplinary Rheumatology.
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.
Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.
Rheumatologists who are outstanding clinicians and provide consistent, exceptional care to patients are in the spotlight in our Lessons from a Master Clinician series. Here, we present insights from a clinician who has achieved distinction in the field of rheumatology, serving as a role model for colleagues and trainees. Alan Baer, MD, is currently a…
ACR CONVERGENCE 2020—Among the many ways in which the COVID-19 pandemic has changed the face of modern medicine is the emergence of multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition that shares many features of Kawasaki disease (KD). With this topic in mind, leading pediatric experts from around the world came together…
ACR CONVERGENCE 2020—In patients with connective tissue diseases, such as systemic sclerosis (SSc), pulmonary hypertension (PH) remains one of the leading causes of morbidity and mortality. In her lecture on Friday, Nov. 6, Pulmonary Hypertension: An Update, Mardi Gomberg-Maitland, MD, MSc, professor of medicine and medical director of the Pulmonary Hypertension Program at The George…
ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…
Cancer treatments, organ transplants and rheumatologic diseases—dendritic cells are being used throughout medicine to create innovative treatments, according to presenters of a virtual session during the European e-Congress of Rheumatology.
Advancements in technology and artificial intelligence designed to aid rheumatologists in diagnosing patients and predicting mortality risk were discussed in depth during a session of the European e-Congress of Rheumatology.